Our Company
Our company is focusing on R&D of small-molecule drugs for advancing best-in-class therapies to improve human lives. We are based in the San Francisco Bay Area, Chongqing and Shanghai. We have a proven track record of accelerating the discovery of best-in-class potential small-molecule therapeutics to clinical development for cancer and metabolic diseases. We are supported by excellent management and R&D teams with extensive drug discovery and development expertise. We are now leveraging R&D and commercial expertise from US and China to expand our pipeline globally.
Our Strategies
We seamlessly integrate the art of traditional medicinal chemistry with the modern technology of structure-based drug design. This integration culminates in our proprietary compound generation, optimization and preclinical/clinical development. Our expertise and experience allow us to proficiently and rapidly create a risk-diversified portfolio of drug candidate pipelines.
Fochon News
Fochon Pharmaceuticals, Ltd. (a Subsidiary of Fosun Pharma) Announces Licensing Agreement with Eli Lilly and Company for Novel Selective BCL-2 Inhibitor
Our Pipeline
Our pipeline consists of novel, proprietary and highly-selective targeted therapeutics that are in development to potentially treat a broad array of difficult-to treat indications, including cancer and metabolic diseases. We believe that our pipeline is uniquely positioned to address the limitations of currently available therapies by providing safe and effective treatment solutions.
At Fochon, our mission is to improve people’s lives by discovering breakthrough medicines that advance the care of patients who are suffering from life-threatening diseases.
